Live Stocks are getting hit again as Trump lashes out at the Fed and Powell. See the latest. Frankfurt - Delayed Quote • EUR Smith & Nephew plc (NPWA.F) Follow Compare 22.60 0.00 (0.00%) At close: April 17 at 8:03:47 AM GMT+2 All News Press Releases SEC Filings Are Poor Financial Prospects Dragging Down Smith & Nephew plc (LON:SN. Stock? With its stock down 15% over the past month, it is easy to disregard Smith & Nephew (LON:SN.). Given that stock prices... Is Smith & Nephew plc (SNN) the Most Undervalued Healthcare Stock to Buy According to Analysts? We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Smith & Nephew plc (NYSE:SNN) stands against other most undervalued healthcare stocks to buy according to analysts. Rising Healthcare Costs and the Impact of Tariffs on US-China […] Here's Why We're Wary Of Buying Smith & Nephew's (LON:SN.) For Its Upcoming Dividend Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Smith... Smith & Nephew's (LON:SN.) Solid Earnings Are Supported By Other Strong Factors Smith & Nephew plc's ( LON:SN. ) strong earnings report was rewarded with a positive stock price move. We did some... Smith & Nephew Full Year 2024 Earnings: EPS Misses Expectations Smith & Nephew ( LON:SN. ) Full Year 2024 Results Key Financial Results Revenue: US$5.81b (up 4.7% from FY 2023). Net... Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for Robotics, Knees, Hips, and Shoulders at AAOS 2025 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include: Robotics: Optimizing and personalizing surgery With CORIOGRAPH◊ Pre-Op Planning and Modeling Services advanced technology and the CORI Surgical System's image-agnostic solution for robotic-assisted knee a Smith+Nephew to highlight breakthrough Sports Medicine technologies for joint repair at AAOS 2025 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase the latest advancements in Sports Medicine for joint repair at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include: Spatial Surgery Smith+Nephew continues to pioneer in Sports Medicine and is excited to introduce a new category called Spatial Surgery - a revolutionary new frontier in arthroscopic surgical innova New report confirms Smith+Nephew’s OXINIUM™ Technology is the best performing bearing surface at 20 years for total hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce that the latest annual report from the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) highlights the exceptional performance of Smith+Nephew’s proprietary OXINIUM on highly cross-linked polyethylene. The data indicates that this combination has the highest survivorship rate (94.1%) among all bearing combinations over a 20-year period for total hip arthroplasty (THA).1 Be Wary Of Smith & Nephew (LON:SN.) And Its Returns On Capital If we're looking to avoid a business that is in decline, what are the trends that can warn us ahead of time? Businesses... Smith & Nephew opens door to break-up in response to activist, The Times says Smith & Nephew has opened up to a possible break-up of the company amid activist pressure to consider a separation of its largest segment, its struggling orthopedics division, marking a shift in the company’s public position, reported The Times’ Alex Ralph. In a meeting with City analysts after Smith & Nephew’s full-year results last week, CFO John Rogers said the group remained committed to the turnaround of the largest of the group’s three units, but could consider options if its growth does n Smith+Nephew is pioneering Spatial Surgery – a defining new Sports Medicine category pushing the boundaries of technology and procedural innovation Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces its pioneering efforts to develop technology in the field of Spatial Surgery - a revolutionary new frontier in arthroscopic surgical innovation. We envision Spatial Surgery as an opportunity to provide personalized planning, augmented reality and real-time data processing into platforms that interpret the surgical field intraoperatively. Smith+Nephew has submitted to the FDA a traditional 510(k) for a technol Smith & Nephew PLC (SNN) Full Year 2024 Earnings Call Highlights: Navigating Growth Amidst ... Smith & Nephew PLC (SNN) reports robust revenue growth and margin expansion, while addressing significant headwinds in the Chinese market. Trending tickers: Tesla, Palantir, Alibaba, Unilever and bitcoin The latest investor updates on stocks that are trending on Tuesday. Hip replacement firm Smith & Nephew’s profit surges amid recovery in US sales The medical technology giant has been in the midst of a turnaround effort, and recently faced calls from its top investors to break the company up. Stocks to watch this week: Berkshire Hathaway, Nvidia, Salesforce, IAG and Aston Martin Earnings preview of key companies reporting this week and what to look out for. 3 UK Stocks That May Be Undervalued By The Market The United Kingdom's stock market has recently faced challenges, with the FTSE 100 index experiencing declines due to weak trade data from China and falling commodity prices affecting major companies. Amid these broader market pressures, investors may find opportunities in stocks that appear undervalued by the market, offering potential value based on their fundamentals and resilience in navigating current economic conditions. Smith+Nephew steps forward with innovative Sports Medicine foot & ankle repair solutions in Australia and New Zealand First in market to offer Adjustable Tensioning Technology* for insertional Achilles reconstruction and lateral ankle instability repair *After anchor insertion Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of a comprehensive foot & ankle repair portfolio in Australia and New Zealand (ANZ) with proprietary adjustable tensioning technology. The ULTRABRIDGE◊ Adjustable Achilles Reconstruction and ULTRABRACE◊ Adjustable Ankle Instability Technique Smith & Nephew plc (SNN) Among the 10 Safest Dividend Stocks in the UK We recently published a list of 10 Safest Dividend Stocks in the UK. In this article, we are going to take a look at where Smith & Nephew plc (NYSE:SNN) stands against other safest dividend stocks in the UK. In recent years, investors have increasingly shifted away from UK equities, favoring global stocks, particularly high-growth […] Smith+Nephew and UFC to host first-of-its-kind medical education course for treatment of injuries in combat sport athletes Healthcare professionals are invited to register for the livestream option as a courtesy here Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the inaugural Smith+Nephew UFC Combat Sports Medicine Course to be held in Las Vegas, Nevada from February 20-21, 2025. The course will be chaired by Dr. Michael Banffy from the Cedars-Sinai Kerlan-Jobe Institute in Los Angeles, California and features a roster of world-renowned medical experts to discuss current tre Smith+Nephew’s ALLEVYN™ LIFE Sacrum Foam Dressing and LEAF™ Patient Monitoring System receive ‘favorable’ Evidence Bar™ ratings from ECRI for pressure injury prevention Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that ECRI – leaders in advancing evidence-based healthcare globally - have completed updated Clinical Evidence Assessments of ALLEVYN LIFE Sacrum Foam Dressings and the LEAF Patient Monitoring System. In their latest reports, ECRI upgraded its Evidence Bar ratings for both to favorable* after assessing the most recently published clinical evidence and key outcomes for pressure injury prevention. The ECRI Evid Performance Overview Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) Return NPWA.F FTSE 100 (^FTSE) YTD -2.49% +1.26% 1-Year +3.86% +5.45% 3-Year -13.33% +8.66%